Insulet Corporation reported second quarter 2026 financial results, announcing revenue of $801.7 million, a 23.5% increase from the prior year period. Net income rose to $95.0 million, or $1.37 per diluted share, compared to $22.5 million in the previous year. The company updated its full-year 2026 revenue growth guidance downward to 20%-22% at constant currency, reflecting scaling dynamics in type 2 diabetes markets. Insulet operates as a medical device company specializing in tubeless insulin pump technology and automated insulin delivery systems.
